Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Re-Open 3: OPN-375 in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
NCT06850805Phase 3Recruiting
- Sponsor
- OptiNose
- Start
- Jul 2025
- Primary completion
- Mar 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone propionate nasal spray in chronic rhinosinusitis without nasal polyps (CRSsNP) (2 arms), sponsored by OptiNose. Primary endpoint: Composite Score of Nasal Symptoms at 4 weeks. Started Jul 2025; status: recruiting.
02
Drugs
fluticasone propionate nasal spray
03
Conditions
chronic rhinosinusitis without nasal polyps (CRSsNP)
Beyond the preview
Go deeper on NCT06850805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06850805.